Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Durlaza (aspirin) for Reducing Risk of Cardiovascular Events

Drug Name (Brand / Generic)

Durlaza (aspirin)

Company / Licensee

New Haven Pharmaceuticals

Current Indication

Prevention of cardiovascular events including stroke and myocardial infarction

Market Sector

Cardiovascular

Development Status

Approved in the US
Expand

Go Top